BI's Pradaxa wins expanded use for DVT/pulmonary embolism
This article was originally published in Scrip
Executive Summary
Boehringer Ingelheim won the FDA's blessing to market the company's Pradaxa (dabigatran etexilate mesylate) as a treatment for deep vein thrombosis (DVT) and pulmonary embolism (PE) – conditions collectively referred to as venous thromboembolism (VTE), which can be life-threatening.